SYNCOM
FORMULATIONS (INDIA) LIMITED
A WHO-GMP & ISO 9001:2015 Certified Company
CIN No.: L24239MH1988PLC047759
Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai - 400 093, INDIA, Tel.: +91-22-42824400, Email: sfil87@sfil.in
Corp. Off. : 207, Saket Nagar, Indore - 452 018, INDIA. Tel. : +91-731-2560458 / 2700458, Email : info@sfil.in, Website : www.sfil.in
Works : 256-257, Sector-I, Pithampur, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: +91-7292-403122 / 407039, Email : info@sfil.in

SYNCOM/SE/2026-27 **4th November,2026**

Online filing at: www.listing.bseindia.com and
https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Sandra Kurla Complex, Sandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Sub: Corporate Announcement u/r 29(1)(a) of SEBI (LODR) Regulations, 2015 read with SEBI (PIT) Regulations, 2015 regarding intimation of holding the 3/2026-27 Board Meeting scheduled to be held on Friday, 13th day of November, 2026.

Dear Sir/Ma'am,

Pursuant to Regulation 29(1) (a) of SEBI (LODR) Regulations, 2015 read with SEBI (PIT) Regulations, 2015 as amended from time to time, we are pleased to inform that 3/2026-27 Meeting of the Board of Directors of the Company is scheduled to be held on **Friday** the **13th day of November, 2026** at **3:00 P.M**. **(IST)** at the Corporate Office situated at **207, Saket Nagar, Near Saket Club Indore (M.P.) 452018** to consider and approve the following businesses along with other routine businesses:

a) To consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and half year ended 30th September, 2026;
b) To take on record the Standalone and Consolidated Limited Review Report by Auditors for the Unaudited Financial Results of the Company for the Quarter and half year ended 30th September, 2026.
c) Approval of the Unaudited Statement of Assets and Liabilities for the half year ended on 30th September, 2026
d) Approval of the Unaudited Statement of Cash Flow for the half year ended on 30th September, 2026; and
e) To consider and approve other matter.

We are also in process of filing the aforesaid Intimation u/r 29(1)(a) in the XBRL format within the stipulated time and same shall be hosted on the Website of the Company.

Further, we have already updated the details of trading window closure end date in the system of designated depository in terms of SEBI circular No. SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated 19th July, 2023.

You are requested to please take on record our above said information for your reference and disseminate on the website of the BSE/NSE.

Thanking You,
Yours Faithfully,
For, SYNCOM FORMULATIONS (INDIA) LIMITED

Vaishali Agrawal
Digitally signed by Vaishali Agrawal
Date: 2026.11.04 15:41:08 +05'30'

VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER

CRATUS EVOLVE | CRATUS Optima | CRATUS ICURA Intensive Care Redefined | CRATUS Animal Healthcare | CRATUS RIGHT NUTRITION www.cratuscart.com | SYNCOM MOBILIO